Results 1 to 10 of about 4,903,889 (243)

Re-epithelialization and immune cell behaviour in an ex vivo human skin model

open access: yesScientific Reports, 2020
A large body of literature is available on wound healing in humans. Nonetheless, a standardized ex vivo wound model without disruption of the dermal compartment has not been put forward with compelling justification.
Michael Mildner, Adelheid Elbe-Bürger
exaly   +2 more sources

TIMER2.0 for analysis of tumor-infiltrating immune cells

open access: yesNucleic Acids Research, 2020
Tumor progression and the efficacy of immunotherapy are strongly influenced by the composition and abundance of immune cells in the tumor microenvironment.
Taiwen Li, Jingxin Fu, Zexian Zeng
exaly   +2 more sources

Inferring tumour purity and stromal and immune cell admixture from expression data

open access: yesNature Communications, 2013
Infiltrating stromal and immune cells form the major fraction of normal cells in tumour tissue and not only perturb the tumour signal in molecular studies but also have an important role in cancer biology.
Kosuke Yoshihara   +2 more
exaly   +2 more sources

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

open access: yesJournal of Clinical Oncology, 2018
Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICPi) therapy.
Christina Lacchetti   +2 more
exaly   +2 more sources

Understanding the tumor immune microenvironment (TIME) for effective therapy

open access: yesNature Medicine, 2018
Edward W Roberts   +2 more
exaly   +2 more sources

Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework

open access: yesmAbs, 2023
Optimal pharmacokinetic (PK) properties of therapeutic monoclonal antibodies (mAbs) are essential to achieve the desired pharmacological benefits in patients.
Romain Ollier   +15 more
doaj   +1 more source

The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity

open access: yesNature Communications, 2022
CD28 costimulatory signalling can be suppressed by immune checkpoints, such as CTLA-4 and PD-1. Here the authors describe the design of the fusion therapeutic davoceticept (ALPN-202), based on a variant CD80 extracellular domain engineered to bind PD-L1 ...
Mark F. Maurer   +19 more
doaj   +1 more source

Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD

open access: yesNeurobiology of Disease, 2023
Effective therapies are urgently needed to safely target TDP-43 pathology as it is closely associated with the onset and development of devastating diseases such as frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP) and amyotrophic ...
Tariq Afroz   +25 more
doaj   +1 more source

Home - About - Disclaimer - Privacy